Faouzi Khechana
CEO
Hemostod
HemostOD engineers and manufactures universal platelets from a stable megakaryocytic cell line using advanced microfluidic technologies, providing a scalable and rapid source of high-quality platelets. This technology addresses the need for effective treatments in patients with thrombocytopenia and facilitates targeted delivery of therapeutic agents in regenerative medicine applications.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$556.9KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Patients with thrombocytopenia or HLA immune-refractoriness often face challenges in obtaining effective platelet transfusions due to limited donor availability and immunological incompatibilities. Traditional platelet production methods struggle to meet the demand for high-quality platelets, especially for specialized applications like targeted drug delivery and regenerative medicine.
Solution
HemostOD engineers and manufactures universal, HLA-null platelets from a stable, immortalized megakaryocytic cell line, providing a scalable and consistent source of platelets. Their microfluidic bioreactor technology mimics the physiological generation of platelets, enabling rapid production of large quantities of homogeneous, high-quality platelets. These engineered platelets can be customized with specific surface modifications or drug payloads for targeted delivery to tissues or regenerative medicine applications. HemostOD's platform addresses the limitations of donor-derived platelets by offering an off-the-shelf, readily available product with enhanced functionality.
Target Audience
The primary target audience includes hospitals, transfusion centers, and research institutions seeking a reliable source of universal platelets for treating thrombocytopenia, developing targeted drug delivery systems, and advancing regenerative medicine therapies.
Features
- Immortalized hematopoietic progenitor cell line engineered for stable megakaryocyte production
- Advanced microfluidic bioreactor for efficient platelet generation from megakaryocytes
- Universal platelets engineered to be HLA-null, reducing the risk of immune rejection
- CAR-PLT® technology for targeted delivery of miRNA/siRNA or proteins to specific tissues
- Platelet lysate product to boost cell proliferation in therapeutic stem cell cultures
- Scalable manufacturing process enabling large-volume production
- Customizable platelet surface and content for controlled release of therapeutic agents